225Ac-DOTA-Substance P as a potential radiopharmaceutical for targeted alpha therapy of glioblastoma multiforme

Gliomas, particularly WHO grade IV glioblastoma multiforme (GBM) are one of the most common and aggressive primary types of the cancer of the central nervous system and are composed of morphologically diverse population of cells in the tumour mass. Despite all current forms of treatment such as advanced surgery techniques, radiation therapy and chemotherapy, the life expectancy of patients diagnosed with GBM is 12 to 15 months displaying the worst median overall survival among all human neoplasms. Targeted alpha therapy has been shown to overcome chemo- and radioresistance in vitro and thus presents a promising new approach for therapy of GBM. The findings that high affinity Substance P receptor NK1 is high consistently expressed in primary malignant gliomas and in the intratumoral and peritumoral vasculature makes this receptor a very attractive target for glioma cancer therapy.

MAJKOWSKA PILIP Agnieszka;  RIUS MONTRAVETA Maria;  BRUCHERTSEIFER Frank;  APOSTOLIDIS Christos;  WEIS Mirjam;  BONELLI Milton;  LAURENZA Marta;  MORGENSTERN Alfred; 

2017-08-01

European Commission - Joint Reserach Centre

JRC106139